Artelo biosciences announces positive preclinical efficacy data for art26.12 in osteoarthritis pain at the 35th annual international cannabinoid research society symposium

Art26.12, a novel fabp5 inhibitor, demonstrates sustained analgesic effects without tolerance art26.12, a novel fabp5 inhibitor, demonstrates sustained analgesic effects without tolerance

ARTL Ratings Summary

ARTL Quant Ranking